骆氏肾衰汤对慢性肾衰患者钙磷代谢以及成纤维生长因子23的调节研究  

Clinical research on the Luo's Shenshuai decoction for regulating calcium-phosphate metabolism and fibroblast growth factor 23 in patients with chronic renal failure

作　　者：邓彦彦[1] 熊吉龙[1] 魏玉洁[1] 

机构地区：[1]深圳市中医院,广东深圳518000

出　　处：《中医临床研究》2016年第10期12-14,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:探析骆氏肾衰汤对慢性肾衰患者的钙磷代谢以及成纤维生长因子23的调节作用。方法:选取我院2013年6月-2015年2月收治的100例慢性肾衰患者,将其随机分为两组。对照组应用阿法骨化醇治疗,治疗组应用骆氏肾衰汤颗粒剂,比较两组治疗前后钙、磷代谢情况、成纤维生长因子23水平及不良反应发生率。结果:两组治疗前Ca、P、FGF23水平的差异均无统计学意义(P>0.05);治疗后,两组Ca水平的差异无统计学意义(P>0.05),治疗组P、FGF23水平均低于对照组,差异有统计学意义(P<0.05)。治疗组无明显不良反应,对照组共4例(8.0%)出现不良反应,差异有统计学意义(P<0.05)。结论:骆氏肾衰汤可补肾健脾、益气滋养、通腑泻浊,通过调节FGF23水平等方式进而对磷代谢进行调节,避免钙磷代谢异常所引发的并发症,临床价值大。Objective Regulating calcium-phosphate metabolism and fibroblast growth factor 23 in patients with chronic renal failurewith the Luo’s Shenshuai decoction was investigated. Methods： 100 patients were randomly divided into two groups. The control groupwas treated with alfacalcidol. The treatment group received the Luo’s Shenshuai decoction. Results： Ca level in groups showed no statisticaldifference （P〉0.05）. P and FGF23 levels in the treatment group were lower, with a statistical difference （P〈0.05）. There was no obviousadverse reaction in the treatment group; 4 cases （8.0%） in the control group showed adverse reactions; there was a statistical differencebetween groups （P〈0.05）. Conclusion： The Luo’s Shenshuai decoction showed Bushen Jianpi, Yiqi Ziyang and Tongfu Xiezhuo functions,could regulate FGF23 level for regulating calcium-phosphate metabolism, with less complication and large clinical value.

关 键 词：肾衰患者 骆氏肾衰汤 钙磷代谢 

分 类 号：R692.5[医药卫生—泌尿科学]